Yoonmin Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yoonmin Jang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ju-Young Shin
College of Pharmacy, Seoul National University, Seoul, Republic of Korea
3 shared publications - Hayun Choi
Department of Psychiatry, Veteran Health Service Medical Center, Seoul, Republic of Korea
2 shared publications - Ju Hwan Kim
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2 shared publications - Min Woo Kim
Department of Biohealth Regulatory Science Sungkyunkwan University Suwon South Korea
2 shared publications - Rae Woong Park
Department of Biomedical Informatics Ajou University School of Medicine Suwon Republic of Korea
2 shared publications - Seonghoon Hwang
School of Pharmacy Sungkyunkwan University Suwon South Korea
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Drug Targets and Therapeutics (DTT) - Pharmaceutical Society of Korea in Drug Targets and Therapeutics
- Vol. 5 (2) , 192-200
Colchicine Use and Risk of Cancer in Patients with Gout: A Nationwide Cohort Study
Yoonmin Jang, Chae Min Lee, Yongtai Cho, Minjeong Jeon, Yeo Rang Cho, Ki Hyun Kim, Ju-Young Shin. DTT 2026;5:192-200. https://doi.org/10.58502/DTT.26.0008
- 30 September 2026
- Published by Drug Targets and Therapeutics (DTT) - Pharmaceutical Society of Korea in Drug Targets and Therapeutics
- Vol. 5 (2) , 192-200
Open AccessColchicine Use and Risk of Cancer in Patients with Gout: A Nationwide Cohort Study
Yoonmin Jang, Chae Min Lee, Yongtai Cho, Minjeong Jeon, Yeo Rang Cho, Ki Hyun Kim, Ju-Young Shin. DTT 2026;5:192-200. https://doi.org/10.58502/DTT.26.0008
- Open Access
- 13 January 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1706-1715
Antidepressants and the risk of hyponatremia: A multi‐institutional cohort study using observational medical outcomes partnership—Common Data Model
Aim: Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods: Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023), we identified patients diagnosed with depression who initiated antidepressants, including selective serotonin reuptake inhibitor (SSRI), serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCA) or others (agomelatine, bupropion, mirtazapine, moclobemide and trazodone) for at least 30 days. The index date was defined as the first antidepressant prescription, and four mutually exclusive cohorts were constructed based on the antidepressant class prescribed on index date. Each cohort was compared with all other antidepressants. The primary outcome was incident hyponatremia (serum sodium <135 mmol/L) within the first 180 days. After propensity score stratification, hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression. Fixed‐effect meta‐analysis was used to pool the results from each site. Results: We identified 17 895 (42.6%) patients in SSRI, 7395 (17.6%) in SNRI, 5424 (12.9%) in TCA and 11 322 (26.9%) in other group. The risk of hyponatremia increased within 180 days after SSRI initiation (HR 1.18, 95% CI 1.01–1.38) compared with all other depressants, with a higher risk in patients aged ≥60 years (1.29, 1.06–1.57). No significant association was found for SNRIs (1.05, 0.87–1.27), TCAs (1.03, 0.84–1.26) or other (0.90, 0.77–1.06). Conclusion: Close monitoring of serum sodium levels is essential for SSRI users, especially those aged ≥60 years.
- 13 January 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (6) , 1706-1715
Open AccessAntidepressants and the risk of hyponatremia: A multi‐institutional cohort study using observational medical outcomes partnership—Common Data Model
Aim: Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods: Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023), we identified patients diagnosed with depression who initiated antidepressants, including selective serotonin reuptake inhibitor (SSRI), serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCA) or others (agomelatine, bupropion, mirtazapine, moclobemide and trazodone) for at least 30 days. The index date was defined as the first antidepressant prescription, and four mutually exclusive cohorts were constructed based on the antidepressant class prescribed on index date. Each cohort was compared with all other antidepressants. The primary outcome was incident hyponatremia (serum sodium <135 mmol/L) within the first 180 days. After propensity score stratification, hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression. Fixed‐effect meta‐analysis was used to pool the results from each site. Results: We identified 17 895 (42.6%) patients in SSRI, 7395 (17.6%) in SNRI, 5424 (12.9%) in TCA and 11 322 (26.9%) in other group. The risk of hyponatremia increased within 180 days after SSRI initiation (HR 1.18, 95% CI 1.01–1.38) compared with all other depressants, with a higher risk in patients aged ≥60 years (1.29, 1.06–1.57). No significant association was found for SNRIs (1.05, 0.87–1.27), TCAs (1.03, 0.84–1.26) or other (0.90, 0.77–1.06). Conclusion: Close monitoring of serum sodium levels is essential for SSRI users, especially those aged ≥60 years.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Region-Specific Discrepancies in Antidepressant-Related Adverse Events: A Comparison Between the Korea Adverse Event Reporting System and the WHO VigiBase
Kim MW, et al. J Korean Med Sci. 2026 Nov;41:e300. https://doi.org/10.3346/jkms.2026.41.e300
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessRegion-Specific Discrepancies in Antidepressant-Related Adverse Events: A Comparison Between the Korea Adverse Event Reporting System and the WHO VigiBase
Kim MW, et al. J Korean Med Sci. 2026 Nov;41:e300. https://doi.org/10.3346/jkms.2026.41.e300